Suggested remit: To appraise the clinical and cost effectiveness of tralokinumab within its marketing authorisation for treating moderate to severe atopic dermatitis.
Status In progress
Process STA 2018
ID number 3734

Provisional Schedule

Committee meeting: 1 07 October 2021
Expected publication 15 December 2021

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors Leo Pharma (tralokinumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups National Eczema Society
Professional groups British Association of Dermatologists
  Royal College of Physicians


Associated public health groups None
Comparator companies GlaxoSmithKline (alitretion)
  Novartis Pharmaceuticals (ciclosporin, mycophenolate mofetil)
  Pfizer (methotrexate)
  Sanofi (dupilumab)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups None


Key events during the development of the guidance:

Date Update
09 February 2021 Invitation to participate
05 October 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of tralokinumab for treating moderate to severe atopic dermatitis. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early February 2021. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
05 October 2020 In progress. Topic is in progress
22 July 2020 - 19 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance